Zai Lab stock faces a key ESMO test after Cantor target call

Published on 10/07/2026 at 03:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Zai Lab stock was last at USD 25.58 on October 6, 2026, while Cantor Fitzgerald kept a USD 37 target. Second-quarter revenue reached USD 106.31 million.

ZLAB, US98887Q1040, Illustration mit AI erstellt.

Zai Lab stock was last at USD 25.58 on Nasdaq on October 6, 2026, down 0.16 percent from the prior close. The immediate catalyst is Cantor Fitzgerald's reiterated Overweight rating and USD 37 price target, while the company prepares investors for new oncology data.

Cantor keeps a USD 37 target

According to Investing.com on October 6, 2026, Cantor Fitzgerald reiterated an Overweight rating and a USD 37 price target. The target lies 44.6 percent above the October 6 price, leaving the valuation debate tied to clinical execution rather than a simple trading signal.

The same report said the market expects important evidence from zocilurtatug pelitecan, or zoci, in small cell lung cancer. Cantor Fitzgerald highlighted first-line data and identified response rates and progression-free survival as key tests for the program.

Revenue falls but products improve

Zai Lab reported USD 106.31 million of total revenue for the second quarter of 2026, compared with USD 110.0 million in the second quarter of 2025. Net loss reached USD 50.8 million, versus USD 40.7 million a year earlier, according to The Globe and Mail in its August 6, 2026 earnings-call transcript.

Net product revenue was USD 105.8 million, up 11 percent sequentially, while cash and cash equivalents stood at USD 717.5 million on June 30, 2026. That combination points to a company balancing commercial improvement with continued research spending and a reported quarterly operating loss of USD 76.5 million.

ESMO sets the next checkpoint

Business Wire reported on September 29, 2026 that Zai Lab will present first global data from a zoci trial at the ESMO Congress from October 23 through October 27, 2026. The company also scheduled an investor conference call for October 23 at 8:00 a.m. ET.

The presentation will examine zoci with atezolizumab, with or without carboplatin, in first-line extensive-stage small cell lung cancer. Zai Lab said the dataset will include approximately 60 patients, making response durability and safety the central read-through for the pipeline valuation.

Zai Lab stock stays below its high

On October 6, 2026, Zai Lab stock had a 52-week range of USD 15.96 to USD 33.97, with volume of 1,214,235 shares and market capitalization of USD 2.9 billion. The last price was 24.7 percent below the 52-week high, so the ESMO readout remains the next concrete test for the premium embedded in the USD 37 target.